Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2026
Kewaunee Scientific (NASDAQ: KEQU) reported strong Q1 FY2026 results with sales reaching $71.1 million, up 46.9% year-over-year. The company achieved net earnings of $3.1 million ($1.04 per diluted share), compared to $2.2 million ($0.74 per share) in the prior year.
The company's order backlog stood at $205.0 million as of July 31, 2025, up from $159.4 million year-over-year. Domestic segment sales increased 53.0% to $54.4 million, while International segment sales grew 30.2% to $16.8 million. The growth was partially driven by the incorporation of Nu Aire's results, following its acquisition in November 2024.
Despite anticipating uneven quarterly performance for the remainder of FY2026, management expects to deliver improved unadjusted EBITDA compared to FY2025, while continuing strategic investments in corporate infrastructure.
[ "Sales increased significantly by 46.9% to $71.1 million year-over-year", "Net earnings grew 41% to $3.1 million compared to prior year", "Strong order backlog of $205.0 million, up 28.6% from prior year", "Domestic segment sales surged 53.0% to $54.4 million", "International segment sales increased 30.2% to $16.8 million", "Debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1" ]Kewaunee Scientific (NASDAQ: KEQU) ha pubblicato solidi risultati per il primo trimestre dell’esercizio 2026: i ricavi sono saliti del 46,9% su base annua, raggiungendo $71,1 milioni. L’azienda ha realizzato un utile netto di $3,1 milioni (pari a $1,04 per azione diluita), rispetto ai $2,2 milioni ($0,74 per azione) dell’anno precedente.
Il portafoglio ordini al 31 luglio 2025 era di $205,0 milioni, in aumento rispetto ai $159,4 milioni dell’anno precedente. Le vendite sul mercato interno sono cresciute del 53,0%, arrivando a $54,4 milioni, mentre quelle internazionali sono aumentate del 30,2% a $16,8 milioni. Una parte della crescita riflette l’inclusione dei risultati di Nu Aire, acquisita nel novembre 2024.
La direzione prevede una performance trimestrale irregolare per il resto dell’esercizio 2026, ma si attende un miglioramento dell’EBITDA non rettificato rispetto al 2025, continuando al contempo gli investimenti strategici nelle infrastrutture aziendali.
- Vendite +46,9% a $71,1 milioni anno su anno
- Utile netto in crescita del 41% a $3,1 milioni rispetto all’anno precedente
- Portafoglio ordini solido: $205,0 milioni, +28,6% su base annua
- Vendite domestiche +53,0% a $54,4 milioni
- Vendite internazionali +30,2% a $16,8 milioni
- Rapporto debito/patrimonio migliorato a 0,94:1 rispetto a 0,99:1
Kewaunee Scientific (NASDAQ: KEQU) presentó sólidos resultados en el primer trimestre del ejercicio 2026: las ventas aumentaron un 46,9% interanual, alcanzando $71,1 millones. La compañía obtuvo beneficio neto de $3,1 millones (equivalente a $1,04 por acción diluida), frente a $2,2 millones ($0,74 por acción) del año anterior.
El pedido pendiente al 31 de julio de 2025 era de $205,0 millones, superior a los $159,4 millones del año previo. Las ventas en el segmento doméstico subieron un 53,0% hasta $54,4 millones, y las del segmento internacional crecieron un 30,2% hasta $16,8 millones. Parte del crecimiento se debe a la incorporación de los resultados de Nu Aire, adquirida en noviembre de 2024.
La dirección espera un desempeño trimestral desigual durante el resto del ejercicio 2026, pero prevé una mejora del EBITDA no ajustado respecto a 2025, manteniendo inversiones estratégicas en la infraestructura corporativa.
- Ventas +46,9% a $71,1 millones interanuales
- Beneficio neto +41% a $3,1 millones respecto al año anterior
- Sólida cartera de pedidos: $205,0 millones, +28,6% interanual
- Ventas domésticas +53,0% a $54,4 millones
- Ventas internacionales +30,2% a $16,8 millones
- Ratio deuda/capital mejoró a 0,94:1 desde 0,99:1
Kewaunee Scientific (NASDAQ: KEQU)� 2026 회계연도 1분기에서 견조� 실적� 발표했습니다. 매출은 전년 동기 대� 46.9% 증가� $71.1백만� 기록했고, 순이익은 $3.1백만($1.04 희석 주당순이�)으로 전년� $2.2백만($0.74 주당)� 비해 개선되었습니�.
2025� 7� 31� 기준 수주 잔고� $205.0백만으로 전년� $159.4백만에서 늘었습니�. 국내 부� 매출은 53.0% 증가� $54.4백만, 국제 부� 매출은 30.2% 증가� $16.8백만� 기록했습니다. 이러� 성장은 2024� 11� 인수� Nu Aire� 실적 편입� 일부 기인합니�.
경영진은 2026 회계연도 나머지 기간 동안 분기� 실적� 불규칙할 것으� 예상하지�, 2025년보� 개선� 비조� EBITDA� 달성� 것으� 기대하며 기업 인프라에 대� 전략� 투자� 계속� 예정입니�.
- 매출 전년 대� 46.9% 증가, $71.1백만
- 순이� 41% 증가, $3.1백만
- 수주 잔고 견조: $205.0백만, 전년 대� +28.6%
- 국내 매출 53.0% 증가, $54.4백만
- 국제 매출 30.2% 증가, $16.8백만
- 부채비�(부�/자본) 0.99에서 0.94� 개선
Kewaunee Scientific (NASDAQ: KEQU) a publié de solides résultats pour le 1er trimestre de l’exercice 2026 : les ventes ont augmenté de 46,9% en glissement annuel pour atteindre 71,1 M$. La société a réalisé un bénéfice net de 3,1 M$ (soit 1,04 $ par action diluée), contre 2,2 M$ (0,74 $ par action) l’an précédent.
Le carnet de commandes au 31 juillet 2025 s’élevait à 205,0 M$, en hausse par rapport à 159,4 M$ un an plus tôt. Les ventes nationales ont progressé de 53,0% à 54,4 M$, tandis que les ventes internationales ont augmenté de 30,2% à 16,8 M$. Cette croissance reflète en partie l’intégration des résultats de Nu Aire, acquis en novembre 2024.
La direction anticipe des performances trimestrielles irrégulières pour le reste de l’exercice 2026, mais s’attend à une amélioration de l’EBITDA non retraité par rapport à 2025, tout en poursuivant des investissements stratégiques dans l’infrastructure du groupe.
- Ventes +46,9% à 71,1 M$ en glissement annuel
- Bénéfice net +41% à 3,1 M$ par rapport à l’an précédent
- Carnet de commandes solide : 205,0 M$, +28,6% sur un an
- Ventes nationales +53,0% à 54,4 M$
- Ventes internationales +30,2% à 16,8 M$
- Ratio dette/fonds propres amélioré à 0,94:1 contre 0,99:1
Kewaunee Scientific (NASDAQ: KEQU) meldete starke Ergebnisse für das erste Quartal des Geschäftsjahres 2026: Der Umsatz stieg um 46,9% gegenüber dem Vorjahr auf $71,1 Mio.. Das Unternehmen erzielte einen Reingewinn von $3,1 Mio. (entsprechend $1,04 je verwässerter Aktie) gegenüber $2,2 Mio. ($0,74 je Aktie) im Vorjahr.
Der Auftragsbestand belief sich zum 31. Juli 2025 auf $205,0 Mio., nach $159,4 Mio. im Vorjahr. Die inländischen Umsätze wuchsen um 53,0% auf $54,4 Mio., die internationalen Umsätze um 30,2% auf $16,8 Mio.. Ein Teil des Wachstums ist auf die Einbeziehung der Ergebnisse von Nu Aire zurückzuführen, das im November 2024 übernommen wurde.
Das Management erwartet für den weiteren Verlauf des Geschäftsjahres 2026 ungleichmäßig verlaufende Quartale, rechnet aber mit einer Verbesserung des unbereinigten EBITDA gegenüber 2025 und setzt gleichzeitig strategische Investitionen in die Unternehmensinfrastruktur fort.
- Umsatz +46,9% auf $71,1 Mio. gegenüber dem Vorjahr
- Reingewinn +41% auf $3,1 Mio. gegenüber dem Vorjahr
- Starker Auftragsbestand: $205,0 Mio., +28,6% gegenüber dem Vorjahr
- Inländische Umsätze +53,0% auf $54,4 Mio.
- Internationale Umsätze +30,2% auf $16,8 Mio.
- Verschuldungsgrad verbesserte sich von 0,99:1 auf 0,94:1
- None.
- Project delivery timelines experiencing volatility, expecting uneven performance in upcoming quarters
- Increased corporate costs due to strategic investments and compliance requirements
- Corporate segment pre-tax net loss increased to $3.1 million from $2.0 million year-over-year
- Challenging market conditions due to uncertain government policy and geopolitical issues
Insights
Kewaunee reports robust Q1 growth with 46.9% higher sales and 61.3% increased pre-tax earnings, though warning of uneven future performance.
Kewaunee Scientific's Q1 FY2026 results demonstrate impressive growth across key metrics. Sales jumped
The company's order backlog stands at
Segment performance reveals the domestic market as the primary growth driver, with sales increasing
Despite these strong results, management has cautioned investors about potential quarterly volatility for the remainder of FY2026, particularly starting in Q2. The warning stems from project delivery timeline fluctuations amid challenging market conditions, including "uncertain government policy, evolving tariff structures and broader geopolitical upheaval."
The balance sheet shows
Management's strategic investments in corporate infrastructure are creating near-term pressure on the bottom line (corporate segment loss increased to
Fiscal Year 2026 First Quarter Results:
Sales during the first quarter of fiscal year 2026 were
The Company's order backlog was
Domestic Segment- Domestic sales for the quarter were
International Segment- International sales for the quarter were
Corporate Segment� Corporate segment pre-tax net loss was
Total cash on hand on July 31, 2025, was
The Company had short-term debt of
"Our Domestic and International segments delivered solid financial performance in the first quarter despite challenging market conditions as a result of uncertain government policy, evolving tariff structures and broader geopolitical upheaval," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "While our overall backlog remains near historically high levels, we are experiencing volatility in project delivery timelines that we expect will cause uneven performance by quarter for the balance of fiscal year 2026, likely starting in the second quarter. This is a reality of both the uncertainty in the market, and the nature of construction-related manufacturing, where project timing often shifts, causing peaks and valleys in production schedules."
"Kewaunee is focused on growth, both organically and inorganically, and is committed to making strategic investments in the people, processes, and technology that will support and enable this growth in a sustainable manner. These important investments are accounted for in the Corporate segment and, while some of the costs are expected to be non-recurring in nature, many of them will not be. Though this will place pressure on earnings growth in the near term, we believe it will position Kewaunee for rapid and sustained growth in the future, allowing us to gain leverage on these investments over the long term."
"Despite our anticipation of uneven quarterly performance for the remainder of fiscal year 2026, and increasing strategic investment in the Corporate platform, we expect to deliver better unadjusted EBITDA in fiscal year 2026 than we did in fiscal year 2025. We are confident in the strategies we are employing and the long-term health of the business."
1EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure. |
EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation (Unaudited) ($ in thousands) | ||||||||
Quarter Ended July 31, 2024 | Domestic | International | Corporate | Consolidated | ||||
Net Earnings (Loss) | $ 2,871 | $ 463 | $ (1,141) | $ 2,193 | ||||
Add/(Less): | ||||||||
Interest Expense | 441 | 21 | 10 | 472 | ||||
Interest Income | � | (174) | (173) | (347) | ||||
Income Taxes | 764 | 279 | (851) | 192 | ||||
Depreciation and Amortization | 662 | 107 | 46 | 815 | ||||
EBITDA | $ 4,738 | $ 696 | $ (2,109) | $ 3,325 | ||||
Professional Fees2 | � | � | 730 | 730 | ||||
Adjusted EBITDA | $ 4,738 | $ 696 | $ (1,379) | $ 4,055 | ||||
Quarter Ended July 31, 2025 | Domestic | International | Corporate | Consolidated | ||||
Net Earnings (Loss) | $ 4,722 | $ 643 | $ (2,272) | $ 3,093 | ||||
Add/(Less): | ||||||||
Interest Expense | 313 | 13 | 732 | 1,058 | ||||
Interest Income | � | (131) | (10) | (141) | ||||
Income Taxes | 1,113 | 434 | (786) | 761 | ||||
Depreciation and Amortization | 1,428 | 96 | 25 | 1,549 | ||||
EBITDA | $ 7,576 | $ 1,055 | $ (2,311) | $ 6,320 | ||||
Professional & Other Fees3 | � | � | 224 | 224 | ||||
Adjusted EBITDA | $ 7,576 | $ 1,055 | $ (2,087) | $ 6,544 | ||||
2 Professional and other fees incurred during the three months ended July 31, 2024 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024 |
3 Professional and other fees incurred during the three months ended July 31, 2025 related to the Company's integration of its newly acquired subsidiary, Nu Aire |
Adjusted Consolidated Statement of Operations Reconciliation (Unaudited) ($ in thousands, except per share amounts) | |||||||
Three Months Ended July 31, | |||||||
As Reported | Professional | Adjusted | Adjusted | ||||
Net sales | $ 71,104 | $ � | $ 71,104 | $ 48,393 | |||
Cost of products sold | 50,174 | � | 50,174 | 35,905 | |||
Gross profit | 20,930 | � | 20,930 | 12,488 | |||
Operating expenses | 16,120 | 224 | 15,896 | 9,183 | |||
Operating profit | 4,810 | 224 | 5,034 | 3,305 | |||
Other income, net | 168 | � | 168 | 327 | |||
Interest expense | (1,058) | � | (1,058) | (472) | |||
Profit before income taxes | 3,920 | 224 | 4,144 | 3,160 | |||
Income tax (benefit) expense | 761 | 49 | 810 | 345 | |||
Net earnings | 3,159 | 175 | 3,334 | 2,815 | |||
Less: Net earnings attributable to the non-controlling interest | 66 | � | 66 | 45 | |||
Net earnings attributable to Kewaunee Scientific Corporation | $ 3,093 | $ 175 | $ 3,268 | $ 2,770 | |||
Net earnings per share attributable to Kewaunee Scientific | |||||||
Basic | $ 1.08 | $ 0.06 | $ 1.15 | $ 0.97 | |||
Diluted | $ 1.04 | $ 0.06 | $ 1.10 | $ 0.93 |
4 Professional and other fees incurred during the three months ended July 31, 2025 related to the Company's integration of its newly acquired subsidiary, Nu Aire, including the estimated tax impact |
About Non-GAAP Measures
The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the integration of the Company's newly acquired subsidiary, Nu Aire, Inc., and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.
EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's integration of its newly acquired subsidiary, Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to interest expense and interest income, income taxes, depreciation, amortization or the costs incurred related to the integration of Nu Aire, Inc., which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.
About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in
Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in
Learn more at the companies' websites, located at and .
This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at and on the SEC website at . These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Kewaunee Scientific Corporation Condensed Consolidated Statements of Operations (Unaudited) ($ and shares in thousands, except per share amounts) | |||
Three Months Ended July 31, | |||
2025 | 2024 | ||
Net sales | $ 71,104 | $ 48,393 | |
Cost of products sold | 50,174 | 35,905 | |
Gross profit | 20,930 | 12,488 | |
Operating expenses | 16,120 | 9,913 | |
Operating profit | 4,810 | 2,575 | |
Other income, net | 168 | 327 | |
Interest expense | (1,058) | (472) | |
Profit before income taxes | 3,920 | 2,430 | |
Income tax expense | 761 | 192 | |
Net earnings | 3,159 | 2,238 | |
Less: Net earnings attributable to the non-controlling interest | 66 | 45 | |
Net earnings attributable to Kewaunee Scientific Corporation | $ 3,093 | $ 2,193 | |
Net earnings per share attributable to Kewaunee Scientific Corporation | |||
Basic | $ 1.08 | $ 0.77 | |
Diluted | $ 1.04 | $ 0.74 | |
Weighted average number of common shares outstanding | |||
Basic | 2,851 | 2,849 | |
Diluted | 2,963 | 2,967 |
Kewaunee Scientific Corporation Condensed Consolidated Balance Sheets ($ in thousands) | |||
July 31, 2025 | April 30, 2025 | ||
(Unaudited) | |||
Assets | |||
Cash and cash equivalents | $ 19,489 | $ 14,942 | |
Restricted cash | 952 | 2,222 | |
Receivables, less allowances | 56,897 | 62,384 | |
Inventories | 34,923 | 32,849 | |
Prepaid expenses and other current assets | 4,887 | 5,966 | |
Total Current Assets | 117,148 | 118,363 | |
Net property, plant and equipment | 22,781 | 23,174 | |
Right of use assets | 12,022 | 12,965 | |
Deferred income taxes | 4,211 | 3,994 | |
Net intangible assets | 17,447 | 17,831 | |
Goodwill | 12,487 | 12,487 | |
Other assets | 7,390 | 5,840 | |
Total Assets | $ 193,486 | $ 194,654 | |
Liabilities and Stockholders' Equity | |||
Short-term borrowings | $ 495 | $ 986 | |
Current portion of lease obligations | 3,220 | 3,371 | |
Current portion of financing liability | 807 | 788 | |
Current portion of term loan | 2,903 | 2,903 | |
Accounts payable | 26,327 | 27,033 | |
Other current liabilities | 16,734 | 18,631 | |
Total Current Liabilities | 50,486 | 53,712 | |
Long-term portion of lease obligations | 8,156 | 8,946 | |
Long-term portion of financing liability | 26,420 | 26,632 | |
Long-term portion of seller note | 24,021 | 23,537 | |
Long-term portion of term loan | 9,686 | 10,412 | |
Other non-current liabilities | 5,848 | 5,170 | |
Total Liabilities | 124,617 | 128,409 | |
Kewaunee Scientific Corporation Equity | 67,078 | 64,457 | |
Non-controlling interest | 1,791 | 1,788 | |
Total Stockholders' Equity | 68,869 | 66,245 | |
Total Liabilities and Stockholders' Equity | $ 193,486 | $ 194,654 |
Contact: | Donald T. Gardner III |
704/871-3274 |
View original content to download multimedia:
SOURCE Kewaunee Scientific Corporation